Content Validity and Cognitive Debriefing of a Patient-Reported Outcome Instrument Evaluating Symptoms and Disease Impact in Patients with Geographic Atrophy.
Clinical outcomes assessment
Cognitive debriefing
Content validity
Geographic atrophy
Patient-reported outcomes
Vision
Visual acuity
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
24
10
2022
accepted:
26
01
2023
pubmed:
14
2
2023
medline:
14
2
2023
entrez:
13
2
2023
Statut:
ppublish
Résumé
Geographic atrophy (GA) occurs in the later stages of dry age-related macular degeneration (AMD) and impairs visual acuity, eventually causing permanent blindness in some patients and impacting patient quality of life. Patient-reported outcome (PRO) measures that assess the experience of patients with visual impairment do not sufficiently capture all concepts salient to patients with GA. In this study the experience of patients with GA secondary to dry AMD was evaluated, and items from the novel 10-item Visual Impairment Symptom Severity Assessment (VISSA-10) PRO instrument were mapped to salient symptoms to assess its content validity, ease of use, and relevance. Concept elicitation interviews were conducted with patients with GA to determine salient symptoms and impacts of GA, and a conceptual model was developed to reflect these. The items in the VISSA-10 instrument were then mapped onto the salient symptoms included in this conceptual model. Cognitive debriefing interviews were also conducted with the same cohort to determine the comprehensiveness and comprehensibility of the instrument, and to qualitatively assess levels of change considered meaningful by patients. In total, 25 symptoms and 36 impacts were reported by 19 patients with GA, with seven symptoms and 11 impacts identified as salient. Of these, 12 symptoms and 15 impacts reported were not included in a previously published conceptual model for patients with dry AMD. Overall, eight of the ten items from the VISSA-10 instrument mapped to salient symptoms reported by patients with GA. All patients reported that the instrument was clear and easy to understand. The VISSA-10 instrument was shown to be content valid, clear, and comprehensible, with sufficient concept coverage to measure the experience of patients with GA. Although further quantitative validation is required, this instrument has demonstrated potential for implementation in future clinical trials to evaluate the efficacy of new treatments for GA.
Identifiants
pubmed: 36781630
doi: 10.1007/s40123-023-00667-3
pii: 10.1007/s40123-023-00667-3
pmc: PMC10011295
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1181-1193Informations de copyright
© 2023. The Author(s).
Références
Deng Y, Qiao L, Du M, et al. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2021;9:62–79.
doi: 10.1016/j.gendis.2021.02.009
pubmed: 35005108
pmcid: 8720701
Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron. 2012;75:26–39.
doi: 10.1016/j.neuron.2012.06.018
pubmed: 22794258
pmcid: 3404137
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Heal. 2014;2:e106–16.
doi: 10.1016/S2214-109X(13)70145-1
Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010;10:31.
doi: 10.1186/1471-2415-10-31
pubmed: 21144031
pmcid: 3009619
Ehrlich R, Harris A, Kheradiya NS, Winston DM, Ciulla TA, Wirostko B. Age-related macular degeneration and the aging eye. Clin Interv Aging. 2008;3:473–82.
doi: 10.2147/CIA.S2777
pubmed: 18982917
pmcid: 2682379
Schultz NM, Bhardwaj S, Barclay C, Gaspar L, Schwartz J. Global burden of dry age-related macular degeneration: a targeted literature review. Clin Ther. 2021;43:1792–818.
doi: 10.1016/j.clinthera.2021.08.011
pubmed: 34548176
Parfitt A, Boxell E, Amoaku WM, Bradley C. Patient-reported reasons for delay in diagnosis of age-related macular degeneration: a national survey. BMJ Open Ophthalmol. 2019;4:e000276.
doi: 10.1136/bmjophth-2019-000276
pubmed: 31750395
pmcid: 6830468
Fleckenstein M, Mitchell P, Freund KB, et al. The progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology. 2018;125:369–90.
doi: 10.1016/j.ophtha.2017.08.038
pubmed: 29110945
Carlton J, Barnes S, Haywood A. Patient perspectives in geographic atrophy (GA): exploratory qualitative research to understand the impact of GA for patients and their families. Br Ir Orthopt J. 2019;15:133–41.
doi: 10.22599/bioj.137
pubmed: 32999984
pmcid: 7510394
Brédart A, Marrel A, Abetz-Webb L, Lasch K, Acquadro C. Interviewing to develop patient-reported outcome (PRO) measures for clinical research: eliciting patients’ experience. Health Qual Life Outcomes. 2014;12:15.
doi: 10.1186/1477-7525-12-15
pubmed: 24499454
pmcid: 3933509
U.S. Food and Drug Administration (FDA). Patient-focused drug development: collecting comprehensive and representative input guidance for industry, Food and Drug Administration staff, and other stakeholders. 2020. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-collecting-comprehensive-and-representative-input . Accessed May 2022.
National Institute for Health and Care Excellence (NICE). Evidence standards framework for digital health technologies. 2018. www.nice.org.uk/corporate/ecd7 . Accessed June 2022.
DeMuro C, Clark M, Doward L, Evans E, Mordin M, Gnanasakthy A. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006–2010). Value Health. 2013;16:1150–5.
doi: 10.1016/j.jval.2013.08.2293
pubmed: 24326168
European Medicines Agency (EMA). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. 2005. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-guidance-use-healthrelated-quality-life-hrql-measures-evaluation_en.pdf . Accessed July 2022.
Mangione C, Lee P, Gutierrez P, et al. Development of the 25-item national eye institute visual function questionnaire. Arch Opthalmol. 2001;119:1050–8.
doi: 10.1001/archopht.119.7.1050
Sivaprasad S, Tschosik EA, Guymer RH, et al. Living with geographic atrophy: an ethnographic study. Ophthalmol Ther. 2019;8:115–24.
doi: 10.1007/s40123-019-0160-3
pubmed: 30706242
pmcid: 6393253
Schultz NM, Braunack-Mayer L, Schwartz J, Gaspar L. The patient experience: symptoms and impact of dry age-related macular degeneration. Ophthalmol Ther. 2021;10:151–64.
doi: 10.1007/s40123-020-00325-y
pubmed: 33512689
pmcid: 7886930
Schultz N, Braunack-Mayer L, Schwartz J, Gaspar L. PRO70 patient-reported outcomes (PRO) landscape assessment of dry age-related macular degeneration (AMD): a targeted literature review. Value Health. 2020;23:S340–1.
doi: 10.1016/j.jval.2020.04.1291
Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity - Establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2—assessing respondent understanding. Value Health. 2011;14:978–88.
doi: 10.1016/j.jval.2011.06.013
pubmed: 22152166
Turner-Bowker DM, Lamoureux RE, Stokes J, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21:839–42. https://doi.org/10.1016/j.jval.2017.11.014 .
doi: 10.1016/j.jval.2017.11.014
pubmed: 30005756
Patel PJ, Ziemssen F, Ng E, et al. Burden of illness in geographic atrophy: a study of vision-related quality of life and health care resource use. Clin Ophthalmol. 2020;14:15–28.
doi: 10.2147/OPTH.S226425
pubmed: 32021065
pmcid: 6955611